NVE (NVEC) Q2 2027 Earnings Call Transcript
NVE (NVEC) reported Q2 2027 earnings with revenue of $16.9M, up 36% YoY. Net income was $3.17M or $0.65 per diluted share. The company expects medical and defense sales to recover and revenues in H2 to match H1. Operating expenses increased 4% YoY, with a 44% rise in SG&A and a 17% drop in R&D. The effective tax rate decreased to 14% due to favorable tax law changes. NVE announced new products in sensors and gear sensors, focusing on automation and robotics.
How this was made

The 30-second read
Why it matters
The earnings beat and dividend announcement provide fresh positive catalysts for the stock, likely prompting short‑term buying interest.
Market read
First‑report earnings data for a micro‑cap sensor maker, offering a clear trading signal.
What to watch
The decline in R&D spend and reliance on director option grants for SG&A may affect future innovation pipeline.
Background
NVEC (formerly NovaVision) provides wafer‑level chip scale sensors for medical and industrial automation markets.
Ticker impact
Q2 FY2027 earnings call disclosed revenue of $16.9M (+36% YoY), net income $3.17M (+$0.65 EPS) and a quarterly dividend of $1.00 per share.
likely modest upside as investors price in the revenue beat and dividend, though small‑cap liquidity may limit move
The company reported higher revenue, strong margins and a dividend, providing fresh positive data for a micro‑cap stock.
Market effects
Signals strength in medical device and industrial automation segments, potentially supporting peers in the sensor market.
Limited to U.S. micro‑cap investors; no broader regional effect.
Low; impact confined to niche sensor/automation niche.
Counterpoint
Despite earnings beat, the small scale and reliance on distributor sales could expose the stock to volatility if order flow weakens.
Key entities
- ExecutivePeter G. Eames
President and CEO who presented the earnings call.
- ExecutiveDaniel Nelson
CFO who discussed cash flow and dividend details.